Sucampo/Takeda Chronic Constipation Agent Amitiza Indicated For All Adults

Sucampo and marketing partner Takeda's newly approved chronic idiopathic constipation treatment Amitiza is indicated for use in a broader patient population than Novartis' Zelnorm